

---

ongoing trials - trial from [www.clinicaltrials.gov](http://www.clinicaltrials.gov)

## **SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes - Phase 2|Phase 3 - Not yet recruiting**

**Code:** NCT06149793    **Year:** 2023    **Date:** December 30, 2023

**Author:** Amir Moheet|University of Minnesota

### **Study design (if review, criteria of inclusion for studies)**

Interventional - Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment

### **Participants**

Cystic Fibrosis-related Diabetes|Cystic Fibrosis - 18 Years and older (Adult, Older Adult)

### **Interventions**

Drug: Empagliflozin|Other: Placebo Control

### **Outcome measures**

Feasibility, safety, tolerability

<https://ClinicalTrials.gov/show/NCT06149793>

### **Keywords**

Empagliflozin; SGLT2 inhibitors; Hypoglycemic Agents; pharmacological\_intervention;